OrthoPediatrics stock gets full commercial launch for VerteGlide
Published on 11/17/2026 at 01:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew spinal system reaches market
- OrthoPediatrics announced the full commercial launch of VerteGlide on November 9, 2026.
- The system is designed for early onset scoliosis while preserving the potential for continued spinal growth.
- The launch expands the company's scoliosis portfolio and follows adoption during a limited US release.
OrthoPediatrics announced the full commercial launch of its VerteGlide Spinal Growth Guidance System on November 9, 2026. The company said the system is designed for children with Early Onset Scoliosis and follows a limited launch that showed adoption across the United States. The announcement was carried by GlobeNewswire.
Growth guidance for scoliosis
VerteGlide is intended to provide three-dimensional deformity correction while allowing natural growth to continue through additional vertebral segments. That positioning gives surgeons another growth-friendly option for complex spinal deformities, according to the company.
OrthoPediatrics said the launch strengthens its scoliosis portfolio and reflects continued interest among pediatric spine surgeons in growth-guidance technology. The system uses Shilla technology licensed from Medtronic, according to the release.
Specialist medical device portfolio
OrthoPediatrics focuses exclusively on pediatric orthopedics. Its products cover trauma and deformity, scoliosis, and sports medicine and other procedures. The company sells in the United States and more than 75 countries outside the United States.
OrthoPediatrics company facts
- Company: OrthoPediatrics Corp.
- ISIN: US68752L1008
- Ticker: KIDS
- Home exchange: Nasdaq
- Event date: November 9, 2026
The Nasdaq Composite offers the broader US market backdrop for OrthoPediatrics and other Nasdaq-listed companies. Current market coverage tracks developments across that market.
Further company updates and analysis are available in More news and analyses on OrthoPediatrics stock.
